Search alternatives:
larger decrease » marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
e decrease » we decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
i larger » _ larger (Expand Search), i large (Expand Search), a large (Expand Search)
larger decrease » marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
e decrease » we decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
i larger » _ larger (Expand Search), i large (Expand Search), a large (Expand Search)
-
1
The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness.
Published 2025“…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. …”
-
2
<b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>"
Published 2025“…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". …”
-
3
-
4
-
5
CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).
Published 2024“…<p>CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).</p>…”
-
6
-
7
-
8
-
9
-
10
Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation.
Published 2024“…Colors indicate samples from different animals. Large circles show mean of cells from 5 fields of view from a single animal. …”
-
11
Expression of lipid biosynthetic genes is decreased with polyamine depletion.
Published 2024Subjects: -
12
-
13
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
14
-
15
-
16
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
17
-
18
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
19
-
20
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: